Concert.ai

ConcertAI is the leader in predictive and generative AI SaaS and real-world data (RWD) research solutions for healthcare and life sciences, with a primary focus on oncology. Founded in 2018 by Dr. Romesh Wadhwani, the Cambridge, Massachusetts-based company provides a comprehensive platform of AI-powered tools spanning clinical research, drug development, commercial life sciences, and patient care — including external control arms, comparative cohort studies, trial feasibility assessment, precision oncology analytics, and AI-assisted clinical trial matching. ConcertAI acquired CancerLinQ from ASCO in 2023 and TeraRecon (advanced medical imaging). The company employs over 800 people, is valued at approximately $1.9 billion, and has raised over $300M. Its clients include leading pharmaceutical companies such as Novartis, AbbVie, Bayer, Bristol-Myers Squibb, AstraZeneca, Regeneron, Amgen, and Merck.